In a recent Phase II study, hu14.18-IL2 induced complete regression of neuroblastoma lesions in five out of 23 patients with minimal disease evaluable only by [123I] metaiodo benzylguanidine (MIBG) scintigraphy and/or bone marrow (BM) histology. This evidence concerns the gene IL2 and neuroblastoma.